Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

被引：14

作者：

Foran, James M. ^{[1
]}

DiNardo, Courtney D. ^{[2
]}

Watts, Justin M. ^{[3
]}

Stein, Eytan M. ^{[4
]}

De Botton, Stephane ^{[5
]}

Fathi, Amir T. ^{[6
]}

Prince, Gabrielle T. ^{[7
]}

Stein, Anthony ^{[8
]}

Stone, Richard M. ^{[9
]}

Patel, Prapti A. ^{[10
]}

Tallman, Martin S. ^{[4
]}

Choe, Sung ^{[11
]}

Wang, Hongfang ^{[11
]}

Zhang, Vickie ^{[11
]}

Fan, Bin ^{[11
]}

Yen, Katharine E. ^{[11
]}

Oluyadi, Abdulafeez ^{[11
]}

Winkler, Thomas ^{[11
]}

Hickman, Denice ^{[11
]}

Agresta, Samuel V. ^{[11
]}

Liu, Hua ^{[11
]}

Wu, Bin ^{[11
]}

Attar, Eyal C. ^{[11
]}

Kantarjian, Hagop M. ^{[2
]}

机构：

[1] Mayo Clin Florida, Jacksonville, FL USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Inst Gustave Roussy, Villejuif, France

[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[7] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[11] Agios Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123946

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4254

引用

页数：4

共 50 条

[41] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
De la Fuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory M.
Burris, Howard
Janku, Filip
Huang, Ray
Young, Robert J.
Ellingson, Benjamin
Nimkar, Tara
Jiang, Liewen
Ishii, Yuko
Choe, Sung
Fan, Bin
Steelman, Lori
Yen, Katharine
Bowden, Chris
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2017, 19 : 10 - 11
[42] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
Fan, Bin
Abou-Alfa, Ghassan K.
Zhu, Andrew X.
Pandya, Shuchi S.
Jia, Hongxia
Yin, Feng
Gliser, Camelia
Hua, Zhaowei
Hossain, Mohammad
Yang, Hua
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 471 - 479
[43] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
Bin Fan
Ghassan K. Abou-Alfa
Andrew X. Zhu
Shuchi S. Pandya
Hongxia Jia
Feng Yin
Camelia Gliser
Zhaowei Hua
Mohammad Hossain
Hua Yang
Cancer Chemotherapy and Pharmacology, 2024, 93 : 471 - 479
[44] Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
Dai, David
Dinardo, Courtney Denton
Stein, Eytan
de Botton, Stephane
Attar, Eyal C.
Liu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
DiNardo, Courtney D.
Stein, Anthony S.
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Doehner, Hartmut
Martinelli, Giovanni
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Lam, Du
Wang, Xiwei
Gong, Jing
Kapsalis, Stephanie M.
Hickman, Denice
Zhang, Vickie
Winkler, Thomas
Daigle, Scott
Vyas, Paresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
[46] Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
Birendra, K. C.
DiNardo, Courtney D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (08): : 460 - 465
[47] Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses
Wang, Hongfang
Choe, Sung
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Fathi, Amir T.
Tallman, Martin S.
Kantarjian, Hagop M.
Stone, Richard M.
Quek, Lynn
Zhang, Vickie
Liu, Hua
Attar, Eyal C.
Wu, Bin
BLOOD, 2019, 134
[48] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
Dinardo, Courtney Denton
Stein, Anthony Selwyn
Stein, Eytan M.
Fathi, Amir Tahmasb
Frankfurt, Olga
Schuh, Andre C.
Martinelli, Giovanni
Patel, Prapti Arvind
Raffoux, Emmanuel
Tan, Peter
Zeidan, Amer Methqal
de Botton, Stephane
Kantarjian, Hagop M.
Stone, Richard M.
Lam, Du Hung
Gong, Jing
Zhang, Vickie
Winkler, Thomas
Wu, Bin
Vyas, Paresh
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
DiNardo, Courtney
de Botton, Stephane
Pollyea, Daniel A.
Stein, Eytan M.
Fathi, Amir T.
Roboz, Gail J.
Collins, Robert
Swords, Ronan T.
Flinn, Ian W.
Altman, Jessica K.
Tallman, Martin S.
Kantarjian, Hagop M.
Derti, Adnan
Goldwasser, Meredith
Prahl, Malia
Wu, Bin
Yen, Katherine
Agresta, Sam
Stone, Richard M.
BLOOD, 2015, 126 (23)
[50] Evaluation of drug-drug interaction of itraconazole and ivosidenib (AG-120), an oral, potent, targeted, small molecule inhibitor of mutant IDH1, in healthy subjects
Fan, B.
Prakash, C.
Liu, H.
Liu, G.
Korth, C.
Yang, H.
Dai, D.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E40 - E41

← 1 2 3 4 5 →